Ocuphire Presenting New Data and Updates on APX3330 and Nyxo

New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients... | January 31, 2022

Related Keywords

, David Boyer , James Katz , Kols Jay Pepose , Bindu Manne , Mina Sooch , Mitchell Jackson , Peter Kaiser , Kolspaul Karpecki , Corey Davis , Kols Mark Kelley , Ocuphire Pharma , Head Of Market Development , Nasdaq , Ocuphire Pharma Inc , Investor Rd Day , Key Opinion Leaders , Diabetic Retinopathy , Mark Kelley , Paul Karpecki , Market Development , Jay Pepose , New Drug Applications , Anticipated Milestones , Nyxol Phase , Vision Disturbances , Diabetic Macular Edema , Private Securities Litigation Reform Act , Nc Stock Exchange , News , Information , Press Release , Few , Data , Support , Hase , Development , F , Yxol , Alone , Us , Durable , Single , Eye , Drop , Or , The , Potential , Treatment , Presbyopia , First , Update , N , Recruitment , Px3330 , B Ocup Us67577r1023 ,